blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2752428

EP2752428 - Humanization of rabbit antibodies using a universal antibody framework [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.09.2020
Database last updated on 02.07.2024
FormerThe patent has been granted
Status updated on  11.10.2019
FormerGrant of patent is intended
Status updated on  07.02.2019
FormerExamination is in progress
Status updated on  11.11.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
NOVARTIS AG
Lichtstrasse 35
4056 Basel / CH
[2020/02]
Former [2014/28]For all designated states
ESBATech, an Alcon Biomedical Research Unit LLC
Wagistrasse 21
8952 Schlieren / CH
Inventor(s)01 / Borras, Leonardo
Bundentalstrasse 1
8952 Schlieren / CH
02 / Urech, David
Sonnenblickstr. 8
8645 Jona / CH
 [2014/28]
Representative(s)Grünecker Patent- und Rechtsanwälte PartG mbB
Leopoldstraße 4
80802 München / DE
[2019/46]
Former [2014/28]Grünecker, Kinkeldey, Stockmair & Schwanhäusser
Leopoldstrasse 4
80802 München / DE
Application number, filing date14162664.825.06.2009
[2014/28]
Priority number, dateUS20080075697P25.06.2008         Original published format: US 75697 P
US20080075692P25.06.2008         Original published format: US 75692 P
US20090155041P24.02.2009         Original published format: US 155041 P
US20090155105P24.02.2009         Original published format: US 155105 P
CH2009000083202.06.2009         Original published format: CH 8322009
[2014/28]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2752428
Date:09.07.2014
Language:EN
[2014/28]
Type: B1 Patent specification 
No.:EP2752428
Date:13.11.2019
Language:EN
[2019/46]
Type: B8 Corrected title page of specification 
No.:EP2752428
Date:26.02.2020
[2020/09]
Search report(s)(Supplementary) European search report - dispatched on:EP21.05.2014
ClassificationIPC:C07K16/24, C07K16/22, A61K39/395, C12N15/13
[2014/28]
CPC:
C07K16/22 (EP,CN,KR,US); C07K16/24 (KR); C07K16/241 (EP,CN,US);
C07K16/18 (US); A61K39/395 (KR); A61K39/3955 (US);
A61K39/39558 (US); A61K47/6877 (EP,US); A61P37/02 (EP);
A61P37/06 (EP); C07K16/30 (US); C07K16/465 (US);
C07K2317/24 (EP,CN,US); C07K2317/31 (CN,US); C07K2317/54 (CN,US);
C07K2317/55 (CN,US); C07K2317/56 (CN,US); C07K2317/565 (CN,US);
C07K2317/567 (EP,CN,US); C07K2317/622 (EP,CN,US); C07K2317/73 (EP,CN,US);
C07K2317/76 (CN,US); C07K2317/90 (CN); C07K2317/92 (EP,CN,US);
C07K2317/94 (CN,US); C07K2319/30 (CN,US); G01N33/53 (RU) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2014/28]
TitleGerman:Humanisierung von Kaninchen-Antikörpern unter Verwendung eines universellen Antikörper-Frameworks[2014/28]
English:Humanization of rabbit antibodies using a universal antibody framework[2014/28]
French:Humanisation d'anticorps de lapins au moyen d'une région charpente d'anticorps universelle[2014/28]
Examination procedure31.03.2014Examination requested  [2014/28]
09.01.2015Amendment by applicant (claims and/or description)
31.03.2016Despatch of a communication from the examining division (Time limit: M06)
29.09.2016Reply to a communication from the examining division
02.11.2016Despatch of a communication from the examining division (Time limit: M04)
21.02.2017Reply to a communication from the examining division
05.07.2017Despatch of a communication from the examining division (Time limit: M04)
15.11.2017Reply to a communication from the examining division
21.02.2018Despatch of a communication from the examining division (Time limit: M04)
03.07.2018Reply to a communication from the examining division
08.02.2019Communication of intention to grant the patent
22.05.2019Fee for grant paid
22.05.2019Fee for publishing/printing paid
22.05.2019Receipt of the translation of the claim(s)
05.06.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
13.06.2019Communication of intention to grant the patent
30.09.2019Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP09768695.0  / EP2307458
Divisional application(s)EP19208570.2  / EP3628686
EP21181805.9  / EP3964526
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20090768695) is  19.05.2014
Opposition(s)14.08.2020No opposition filed within time limit [2020/43]
Fees paidRenewal fee
31.03.2014Renewal fee patent year 03
31.03.2014Renewal fee patent year 04
31.03.2014Renewal fee patent year 05
12.06.2014Renewal fee patent year 06
10.06.2015Renewal fee patent year 07
10.06.2016Renewal fee patent year 08
16.06.2017Renewal fee patent year 09
12.06.2018Renewal fee patent year 10
13.06.2019Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY13.11.2019
EE13.11.2019
HR13.11.2019
LT13.11.2019
LV13.11.2019
MC13.11.2019
MK13.11.2019
MT13.11.2019
IS13.03.2020
LU25.06.2020
[2022/32]
Former [2022/27]CY13.11.2019
EE13.11.2019
HR13.11.2019
LT13.11.2019
LV13.11.2019
MC13.11.2019
MT13.11.2019
IS13.03.2020
LU25.06.2020
Former [2021/15]EE13.11.2019
HR13.11.2019
LT13.11.2019
LV13.11.2019
MC13.11.2019
IS13.03.2020
LU25.06.2020
Former [2021/12]EE13.11.2019
HR13.11.2019
LT13.11.2019
LV13.11.2019
MC13.11.2019
IS13.03.2020
Former [2020/37]EE13.11.2019
HR13.11.2019
LT13.11.2019
LV13.11.2019
IS13.03.2020
Former [2020/26]HR13.11.2019
LT13.11.2019
LV13.11.2019
IS13.03.2020
Former [2020/24]LT13.11.2019
LV13.11.2019
IS13.03.2020
Former [2020/23]LT13.11.2019
LV13.11.2019
Documents cited:Search[A]WO0130393  (LUDWIG INST CANCER RES [US], et al) [A] 1-20 * the whole document *;
 [AD]WO2004016740  (EPITOMICS INC [US], et al) [AD] 1-20 * the whole document *;
 [A]US2005033031  (COUTO FERNANDO JOSE REBELO DO [US]) [A] 1-20 * the whole document *;
 [A]US2005048578  (ZHANG DONGXIAO [US]) [A] 1-20 * the whole document *;
 [Y]WO2005035575  (MEDIMMUNE INC [US], et al) [Y] 1-20 * the whole document *;
 [A]US2006216293  (COUTO FERNANDO J R [US], et al) [A] 1-20 * the whole document *;
 [A]WO2006131013  (ESBATECH AG [CH], et al) [A] 1-20 * the whole document *;
 [Y]WO2007001851  (GENENTECH INC [US], et al) [Y] 1-20 * the whole document * * in particular * * abstract * * page 35, line 35 - page 39, line 19 * * page 43, line 9 - page 44, line 35 * * page 71, line 26 - line 33 * * page 73, line 22 - page 76, line 7 * * claims 1-36 * * figures 1-27 * * example 9 *;
 [Y]WO2007042775  (PHOTOBIOTICS LTD [GB], et al) [Y] 1-20 * the whole document *;
 [Y]WO2007042809  (DOMANTIS LTD [GB], et al) [Y] 1-20 * the whole document *;
 [A]WO2007047112  (LILLY CO ELI [US], et al) [A] 1-20 * the whole document *;
 [A]WO2007124610  (ESBATECH AG [CH], et al) [A] 1-20 * the whole document *;
 [A]WO2007140371  (GENENTECH INC [US], et al) [A] 1-20 * the whole document *;
 [Y]WO2008004834  (ISU ABXIS CO LTD [KR], et al) [Y] 1-20 * the whole document * * in particular * * abstract * * page 1, line 8 - line 13 * * page 7, line 10 - page 11, line 16 * * page 12, line 19 - page 13, line 8 * * page 14, line 16 - page 17, line 22 * * claims 1-17 * * figures 1-10 * * examples 1-14 *;
 [AD]WO2008006235  (ESBATECH AG [CH], et al) [AD] 1-20 * the whole document *;
 [A]EP1918302  (FAN XIAOMIN [US], et al) [A] 1-20 * the whole document *;
 [XPI]WO2008118356  (BIOGEN IDEC INC [US], et al) [XP] 1-5,7,9,12,14-20 * in particular * * abstract * * paragraphs [0015] - [0074] - [0111] - [0149] * * figures 1-29; examples 1-14; claims 1-84 * * the whole document * [I] 6,8,10,11,13;
 [YD]  - HONEGGER A ET AL, "Yet Another Numbering Scheme for Immunoglobulin Variable Domains: An Automatic Modeling and Analysis Tool", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, (20010608), vol. 309, no. 3, ISSN 0022-2836, pages 657 - 670, XP004626893 [YD] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1006/jmbi.2001.4662
 [Y]  - EWERT S ET AL, "Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering", METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, (20041001), vol. 34, no. 2, ISSN 1046-2023, pages 184 - 199, XP004526805 [Y] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.ymeth.2004.04.007
 [Y]  - EWERT S ET AL, "STRUCTURE-BASED IMPROVEMENT OF THE BIOPHYSICAL PROPERTIES OF IMMUNOGLOBULIN VH DOMAINS WITH A GENERALIZABLE APPROACH", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA.; US, (20030218), vol. 42, no. 6, ISSN 0006-2960, pages 1517 - 1528, XP008052212 [Y] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1021/bi026448p
 [YD]  - KNAPPIK A ET AL, "Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, (20000211), vol. 296, no. 1, ISSN 0022-2836, pages 57 - 86, XP004461525 [YD] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1006/jmbi.1999.3444
 [A]  - RADER C ET AL, "THE RABBIT ANTIBODY REPERTOIRE AS A NOVEL SOURCE FOR THE GENERATIONOF THERAPEUTIC HUMAN ANTIBODIES", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, (20000505), vol. 275, no. 18, doi:10.1074/JBC.275.18.13668, ISSN 0021-9258, pages 13668 - 13676, XP001023515 [A] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.275.18.13668
 [A]  - POPKOV M ET AL, "Rabbit Immune Repertoires as Sources for Therapeutic Monoclonal Antibodies: The Impact of Kappa Allotype-correlated Variation in Cysteine Content on Antibody Libraries Selected by Phage Display", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, (20030110), vol. 325, no. 2, ISSN 0022-2836, pages 325 - 335, XP004457536 [A] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0022-2836(02)01232-9
 [A]  - JUNG S ET AL, "IMPROVING IN VIVO FOLDING AND STABILITY OF A SINGLE-CHAIN FV ANTIBODY FRAGMENT BY LOOP GRAFTING", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, (19970101), vol. 10, no. 8, ISSN 0269-2139, pages 959 - 966, XP000971779 [A] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1093/protein/10.8.959
 [A]  - ROCHA R ET AL, "Rabbit monoclonal antibodies show higher sensitivity than mouse monoclonals for estrogen and progesterone receptor evaluation in breast cancer by immunohistochemistry", PATHOLOGY RESEARCH AND PRACTICE, GUSTAV FISCHER, STUTTGART, DE, vol. 204, no. 9, ISSN 0344-0338, (200809), pages 655 - 662, (20080618), XP024098831 [A] 1-20 * Published online 18.06.2008 * * the whole document *

DOI:   http://dx.doi.org/10.1016/j.prp.2008.03.010
 [AP]  - OTTIGER MICHAEL ET AL, "Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, US, (20090201), vol. 50, no. 2, ISSN 0146-0404, pages 779 - 786, XP009116265 [AP] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1167/iovs.08-2372
 [AP]  - FURRER ESTHER ET AL, "Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, US, vol. 50, no. 2, ISSN 0146-0404, (20090201), pages 771 - 778, (20080829), XP009116264 [AP] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1167/iovs.08-2370
 [AP]  - KÜGLER MARKUS ET AL, "Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework.", PROTEIN ENGINEERING, DESIGN & SELECTION : PEDS MAR 2009, (200903), vol. 22, no. 3, ISSN 1741-0134, pages 135 - 147, XP002575212 [AP] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1093/protein/gzn079
by applicantUS4704362
 US4881175
 WO9007861
 US4946778
 US5013653
 US5091513
 US5132405
 US5225539
 US5258498
 US5260203
 US5304489
 WO9409817
 US5455030
 US5476786
 US5482858
 US5693761
 US5741957
 US5837821
 US5849992
 WO0148017
 WO0194585
 WO0202781
 WO03097697
 WO2004016740
 WO2004108721
 WO2005016950
 US7429487
 WO2008144757
    - SCHROFF, CANCER RES, (1985), vol. 45, pages 879 - 85
    - SHAWLER, J IMMUNOL, (1985), vol. 135, pages 1530 - 5
    - DILLMAN, CANCER BIOTHER, (1994), vol. 9, pages 17 - 28
    - BOULIANNE, NATURE, (1984), vol. 312, pages 643 - 6
    - LOBUGLIO, PROC NATL ACAD SCI, (1989), vol. 86, pages 4220 - 4
    - CLARK, IMMUNOL TODAY, (2000), vol. 21, pages 397 - 402
    - RIECHMANN, NATURE, (1988), vol. 332, pages 323 - 7
    - SPIEKER-POLET ET AL., PNAS, (1995), vol. 92, pages 9348 - 52
    - MAUR ET AL., FEBS LETT, (2001), vol. 508, pages 407 - 412
    - WARD ET AL., NATURE, (1989), vol. 341, pages 544 - 546
    - BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 426
    - HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 5883
    - HAMERS-CASTERMAN ET AL., NATURE, (1993), vol. 363, pages 446 - 448
    - DUMOULIN ET AL., PROTEIN SCIENCE, (2002), vol. 11, pages 500 - 515
    - HOLLIGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448
    - ALFTHAN ET AL., PROTEIN ENG., (1995), vol. 8, pages 725 - 731
    - CHOI ET AL., EUR. J. IMMUNOL., (2001), vol. 31, pages 94 - 106
    - HU ET AL., CANCER RES., (1996), vol. 56, pages 3055 - 3061
    - KIPRIYANOV ET AL., J. MOL. BIOL., (1999), vol. 293, pages 41 - 56
    - G. E. MORRIS, Epitope Mapping Protocols in Methods in Molecular Biology, (1996), vol. 66
    - NEEDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, pages 444 - 453
    - HONEGGER, A.; PLUCKTHUN, A., J MOL. BIOL., (2001), vol. 309, pages 657 - 670
    - A. HONEGGER, J.MOL.BIOL., (2001), vol. 309, pages 657 - 670
    - KNAPPIK ET AL., J MOL BINL., (20000201), vol. 296, no. 1, pages 57 - 86
    - PANORCHAN ET AL., J. CELL SCIENCE, (2006), vol. 119, pages 66 - 74
    - LEONG; HIBMA, J. IMMUNOL. METHODS, (2005), vol. 302, pages 116 - 124
    - GAWAZ ET AL., J. CLIN. INVEST, (1991), vol. 88, pages 1128 - 1134
    - ZUBLER ET AL., J. IMMUNOL., (1985), vol. 134, no. 6, pages 3662 - 3668
    - R. TAUB ET AL., J. BIOL CHEM, (1989), vol. 264, pages 259 - 265
    - CARTER ET AL., NUCLEIC ACIDS RES., (1985), vol. 13, pages 4431 - 4443
    - KUNKEL ET AL., PROC. NATL. ACAD. SCI. USA, (1987), vol. 82, page 488
    - HIGUCHI, PCR Protocols, ACADEMIC PRESS, (1990), pages 177 - 183
    - VALLETTE ET AL., NUC. ACIDS RES., (1989), vol. 17, pages 723 - 733
    - WELLS ET AL., GENE, (1985), vol. 34, pages 315 - 323
    - QUEEN ET AL., IMMUNOL. REV., (1986), vol. 89, page 49
    - CO ET AL., J. IMMUNOL., (1992), vol. 148, page 1149
    - HUSTON ET AL., PNAS, (1988), vol. 85, page 5879
    - HO ET AL., GENE, (1989), vol. 77, page 51
    - BIRD ET AL., SCIENCE, (1988), vol. 242, page 423
    - PANTOLIANO ET AL., BIOCHEMISTRY, (1991), vol. 30, page 10117
    - MILENIC ET AL., CANCER RESEARCH, (1991), vol. 51, page 6363
    - TAKKINEN ET AL., PROTEIN ENGINEERING, (1991), vol. 4, page 837
    - KARPOVSKY, J. EXP. MED., (1984), vol. 160, page 1686
    - LIU, MA ET AL., PROC. NATL. ACAD. SCI. USA, (1985), vol. 82, page 8648
    - PAULUS, BEHRING INS. MITT. NO. 78, (1985), pages 118 - 132
    - BRENNAN ET AL., SCIENCE, (1985), vol. 229, pages 81 - 83
    - GLENNIE ET AL., J. LMMUNOT., (1987), vol. 139, pages 2367 - 2375
    - SAITO, G. ET AL., ADV. DRUG DELIV. REV., (2003), vol. 55, pages 199 - 215
    - TRAIL, P.A. ET AL., CANCER IMMUNOL. IMMUNOTHER., (2003), vol. 52, pages 328 - 337
    - PAYNE, G., CANCER CELL, (2003), vol. 3, pages 207 - 212
    - ALLEN, T.M., NAT. REV. CANCER, (2002), vol. 2, pages 750 - 763
    - PASTAN, I.; KREITMAN, R. J., CURR. OPIN. LNVESTIG. DRUGS, (2002), vol. 3, pages I 089 - 1091
    - SENTER, P.D.; SPRINGER, C.J., ADV. DRUG DELIV. REV., (2001), vol. 53, pages 247 - 264
    - "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", AMON ET AL., Monoclonal Antibodies And Cancer Therapy, ALAN R. LISS, INC., (1985), pages 243 - 56
    - "Antibodies For Drug Delivery", HELLSTROM ET AL., Controlled Drug Delivery (2nd Ed.),, MARCEL DEKKER, INC., (1987), pages 623 - 53
    - "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", THORPE ET AL., Monoclonal Antibodies'84: Biological And Clinical Applications, (1985), pages 475 - 506
    - "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", BALDWIN ET AL.,, Monoclonal Antibodies For Cancer Detection And Therapy, ACADEMIC PRESS, (1985), pages 303 - 16
    - THORPE ET AL., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", IMMUNOL. REV., (1982), vol. 62, doi:doi:10.1111/j.1600-065X.1982.tb00392.x, pages 119 - 58, XP001179872

DOI:   http://dx.doi.org/10.1111/j.1600-065X.1982.tb00392.x
    - VINCENT LEE, Peptide and Protein Drug Delivery, MARCEL DEKKER, INC., (1991), pages 247 - 301
    - JONES, A., ADV. DRUG DELIVERY REV., (1993), vol. 10, pages 29 - 90
    - PAUL, S., Antibody Engineering Protocols (Methods in Molecular Biology, HUMANA PR, (1996), page 510
    - ZUBLER ET AL., J. IMMUNOL, (1985), vol. 134, no. 6, pages 3662 - 3668
 WO1985GB00392
 WO2008EP01958
 WO2008CH00285
 WO2008CH00284
 US20080075692
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.